Exagen Inc.
XGN · NASDAQ
Bulios Fair Price
$5.3
38.5% downside
Current Price
$8.62
According to Bulios Fair Price, XGN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Exagen Inc. (XGN) is a biotechnology company focused on developing and commercializing diagnostic tests for autoimmune diseases. Their main product is the VeraStrat test, which assists physicians in deciding on appropriate treatment for patients with lung cancer. Exagen Inc. is known for its innovative approach to developing diagnostic tools and efforts to bring improvements in the treatment of autoimmune diseases. Exagen Inc. (XGN) shares could be suitable for investors who are tracking the biotechnology sector and seeking investment opportunities in the field of autoimmune disease diagnostics and treatment.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
John Aballi
Employees
216
Headquarters
Vista
Upcoming events
Earnings
Upcoming earnings report